Takeda Pharmaceutical (TAK) Expected to Announce Earnings on Thursday

Takeda Pharmaceutical (NYSE:TAK) is projected to post its Q2 2027 results before the market opens on Thursday, October 29th. Analysts expect the company to post earnings of $0.1450 per share and revenue of $7.34 billion for the quarter. Takeda Pharmaceutical has set its FY 2026 guidance at 3.009-3.009 EPS. Individuals can find conference call details on the company’s upcoming Q2 2027 earnings summary page for the latest details on the call scheduled for Thursday, October 29, 2026 at 6:00 AM ET.

Takeda Pharmaceutical (NYSE:TAK) last announced its quarterly earnings results on Thursday, July 30th. The company reported $0.95 earnings per share for the quarter, beating the consensus estimate of $0.41 by $0.54. The business had revenue of $7.50 billion during the quarter, compared to analysts’ expectations of $7.13 billion. Takeda Pharmaceutical had a net margin of 3.80% and a return on equity of 10.95%. On average, analysts expect Takeda Pharmaceutical to post $1.56 EPS for the current fiscal year and $1.40 EPS for the next fiscal year.

Takeda Pharmaceutical Price Performance

Shares of Takeda Pharmaceutical stock opened at $20.44 on Tuesday. The company’s fifty day simple moving average is $18.60 and its two-hundred day simple moving average is $17.44. Takeda Pharmaceutical has a 12-month low of $12.99 and a 12-month high of $20.55. The firm has a market cap of $65.50 billion, a PE ratio of 12.05 and a beta of -0.07. The company has a quick ratio of 0.62, a current ratio of 1.14 and a debt-to-equity ratio of 0.58.

Insider Buying and Selling

In other Takeda Pharmaceutical news, insider Deidre Greenway sold 12,980 shares of the business’s stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $18.11, for a total transaction of $235,067.80. Following the transaction, the insider directly owned 40,049 shares of the company’s stock, valued at approximately $725,287.39. The trade was a 24.48% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, General Counsel Anne Furney sold 30,868 shares of the business’s stock in a transaction on Monday, August 10th. The shares were sold at an average price of $17.10, for a total transaction of $527,842.80. Following the transaction, the general counsel directly owned 204,298 shares in the company, valued at approximately $3,493,495.80. The trade was a 13.13% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 627,457 shares of company stock valued at $10,981,175 over the last three months. Insiders own 0.04% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on TAK shares. Zacks Research downgraded shares of Takeda Pharmaceutical from a “strong-buy” rating to a “hold” rating in a research note on Thursday, October 1st. Wall Street Zen raised Takeda Pharmaceutical from a “hold” rating to a “buy” rating in a research note on Saturday, July 18th. Finally, Weiss Ratings upgraded Takeda Pharmaceutical from a “hold (c-)” rating to a “hold (c)” rating in a report on Thursday, October 8th. Two equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat.com, Takeda Pharmaceutical presently has a consensus rating of “Moderate Buy”.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited is a global biopharmaceutical company headquartered in Tokyo, Japan. The company researches, develops, manufactures and commercializes medicines for patients worldwide, with a focus on areas of significant unmet medical need. Its principal therapeutic areas include gastroenterology, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines.

Takeda’s portfolio includes treatments such as Entyvio for inflammatory bowel disease, Takhzyro for hereditary angioedema, and medicines for certain blood cancers and rare conditions.